Sodium Hydroxide → [3-[(4-Chlorophenyl)methyl]-2-(1,1-dimethylethyl)-3,4,5,6,7,8-hexahydrocyclohepta[d]imidazol-4-yl]acetic acid
反応式
[Cl:1][C:2]1[CH:7]=[CH:6][C:5]([CH2:8][N:9]2[C:13]3[CH:14]([CH2:19][C:20]([O:22]CC)=[O:21])[CH2:15][CH2:16][CH2:17][CH2:18][C:12]=3[N:11]=[C:10]2[C:25]([CH3:28])([CH3:27])[CH3:26])=[CH:4][CH:3]=1.[OH-].[Na+]>CO>[Cl:1][C:2]1[CH:3]=[CH:4][C:5]([CH2:8][N:9]2[C:13]3[CH:14]([CH2:19][C:20]([OH:22])=[O:21])[CH2:15][CH2:16][CH2:17][CH2:18][C:12]=3[N:11]=[C:10]2[C:25]([CH3:28])([CH3:27])[CH3:26])=[CH:6][CH:7]=1参加物
4
反応物 2
生成物 1
試薬・触媒・溶媒 1
実験手順
Intermediate 16 (22 mg) was dissolved in Methanol (1 ml) and treated with sodium hydroxide, 2M aq. (1 mL). The RM was left in solution for 1 hour. The residue was purified by MDAP (Method A). The desired fractions were combined and concentrated under nitrogen blowdown to give the title compound (17 mg). LC/MS MH+ 375, Rt 1.72 min (5 minute run).